Contribution of Glial Cells to Polyglutamine Diseases: Observations from Patients and Mouse Models
Neurotherapeutics · 2023-01 · 20 (1) · 48-66
DOI: 10.1007/s13311-023-01357-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neurotherapeutics, 2023-01. Verfasst von Marija Cvetanovic und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Institute for Translational Neuroscience, University of Minnesota, Minneapolis, USA. Hauptthemen laut MEDLINE: Huntington Disease, Spinocerebellar Ataxias. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 191 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Neurodegenerative diseases are broadly characterized neuropathologically by the degeneration of vulnerable neuronal cell types in a specific brain region. The degeneration of specific cell types has informed on the various phenotypes/clinical presentations in someone suffering from these diseases. Prominent neurodegeneration of specific neurons is seen in polyglutamine expansion diseases including Huntington's disease (HD) and spinocerebellar ataxias (SCA). The clinical manifestations observed in these diseases could be as varied as the abnormalities in motor function observed in those who have Huntington's disease (HD) as demonstrated by a chorea with substantial degeneration of striatal medium spiny neurons (MSNs) or those with various forms of spinocerebellar ataxia (SCA) with an ataxic motor presentation primarily due to degeneration of cerebellar Purkinje cells. Due to the very significant nature of the degeneration of MSNs in HD and Purkinje cells in SCAs, much of the research has centered around understanding the cell autonomous mechanisms dysregulated in these neuronal cell types. However, an increasing number of studies have revealed that dysfunction in non-neuronal glial cell types contributes to the pathogenesis of these diseases. Here we explore these non-neuronal glial cell types with a focus on how each may contribute to the pathogenesis of HD and SCA and the tools used to evaluate glial cells in the context of these diseases. Understanding the regulation of supportive and harmful phenotypes of glia in disease could lead to development of novel glia-focused neurotherapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Institute for Translational Neuroscience, University of Minnesota, Minneapolis, USA.
- Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL, USA. mccgray@uabmc.edu.
ORCID-Profile: Michelle Gray
Förderung
- NINDS NIH HHS
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Cvetanovic, M., & Gray, M. (2023). Contribution of Glial Cells to Polyglutamine Diseases: Observations from Patients and Mouse Models. Neurotherapeutics, 20(1), 48-66. https://doi.org/10.1007/s13311-023-01357-5
Vancouver
Cvetanovic M, Gray M. Contribution of Glial Cells to Polyglutamine Diseases: Observations from Patients and Mouse Models. Neurotherapeutics. 2023;20(1):48-66. doi:10.1007/s13311-023-01357-5
BibTeX
@article{Cvetanovic2023,
author = {Cvetanovic, Marija and Gray, Michelle},
title = {Contribution of Glial Cells to Polyglutamine Diseases: Observations from Patients and Mouse Models},
journal = {Neurotherapeutics},
year = {2023},
volume = {20},
number = {1},
pages = {48--66},
doi = {10.1007/s13311-023-01357-5}
}
EUVIMED